Abstract
Diabetes is on the increase worldwide and greater than 90% are type 2. There are two features to type 2 diabetes: muscle, fat and liver tissues are insulin resistant and β cells lose the ability to secrete insulin. Prior to developing diabetes, however, insulin resistant individuals lose the first-phase insulin secretion response. Transgenic mice lacking insulin receptors in their β cells have no first-phase response. Primary cultures of mouse islets pre-exposed to anti-insulin do not exhibit a first-phase insulin secretion response. That is, β cells, like muscle, fat, and liver, are an insulin sensitive tissue and in the presence of insulin resistance (type 2 diabetes), in the absence of insulin receptors (transgenic mice lacking β cell insulin receptors), or in the absence of constitutively secreted insulin (anti-insulin treatment), β cells are unable to respond properly to post-prandial glucose. The purpose of this report is to review our understanding of the glucose-stimulus response and of insulin signaling, and to suggest why the latter may be necessary for the former to proceed.
Keywords: insulin signaling, islet glucose oxidation, pyruvate dehydrogenase, glucokinase, anti-insulin inhibition of insulin secretion, b cell communication, constitutively secreted insulin
Current Diabetes Reviews
Title: Role of Insulin in Glucose-Stimulated Insulin Secretion in Beta Cells
Volume: 1 Issue: 3
Author(s): H. J. Goren
Affiliation:
Keywords: insulin signaling, islet glucose oxidation, pyruvate dehydrogenase, glucokinase, anti-insulin inhibition of insulin secretion, b cell communication, constitutively secreted insulin
Abstract: Diabetes is on the increase worldwide and greater than 90% are type 2. There are two features to type 2 diabetes: muscle, fat and liver tissues are insulin resistant and β cells lose the ability to secrete insulin. Prior to developing diabetes, however, insulin resistant individuals lose the first-phase insulin secretion response. Transgenic mice lacking insulin receptors in their β cells have no first-phase response. Primary cultures of mouse islets pre-exposed to anti-insulin do not exhibit a first-phase insulin secretion response. That is, β cells, like muscle, fat, and liver, are an insulin sensitive tissue and in the presence of insulin resistance (type 2 diabetes), in the absence of insulin receptors (transgenic mice lacking β cell insulin receptors), or in the absence of constitutively secreted insulin (anti-insulin treatment), β cells are unable to respond properly to post-prandial glucose. The purpose of this report is to review our understanding of the glucose-stimulus response and of insulin signaling, and to suggest why the latter may be necessary for the former to proceed.
Export Options
About this article
Cite this article as:
Goren J. H., Role of Insulin in Glucose-Stimulated Insulin Secretion in Beta Cells, Current Diabetes Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339905774574301
DOI https://dx.doi.org/10.2174/157339905774574301 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design The Effect of Risk Factor Changes on Peripheral Arterial Disease and Cardiovascular Risk
Current Drug Targets - Cardiovascular & Hematological Disorders Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Outcomes in Pregnant Patients with Subclinical Hypothyroidism and Thyroid Autoimmunity: A Critical Appraisal of Recent Randomized Controlled Trials
Endocrine, Metabolic & Immune Disorders - Drug Targets Exciting News from the Messenger
Current Neurovascular Research Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry The Neuropeptide Galanin Benefits Insulin Sensitivity in Subjects with Type 2 Diabetes
Current Protein & Peptide Science The Predictive Value of Vessel-Based Calcium Score in the Detection of Coronary Stenosis
Current Medical Imaging Epidemiological Characteristics and Risk Factors of Tinea Pedis Disease Among Adults Attending Tikrit Teaching Hospital/ Iraq
Infectious Disorders - Drug Targets Dietary Small Molecules and Large-Scale Gene Expression Studies: An Experimental Approach for Understanding their Beneficial Effects on the Development of Malignant and Non-Malignant Proliferative Diseases
Current Medicinal Chemistry Other Activities
Current Bioactive Compounds Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design Mass Spectrometric Quantification of Urinary Netrin-1 Protein in Renal Transplant Recipients
Current Proteomics Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke
Current Pharmaceutical Design From Diabetes to Metabolic Syndrome: A View Point on An Evolving Concept
Current Pharmaceutical Design Editorial [Hot Topic:Dietary Determinants of the Metabolic Syndrome (Guest Editor: Luc Tappy Co-Editors: Jacques Delarue and Kim-Anne Le)]
Current Nutrition & Food Science Atherosclerosis and Inflammation: Insight from Carotid and Intracoronary Ultrasound Studies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design Emerging Therapies for Diabetic Neuropathy: A Clinical Overview
Current Diabetes Reviews Advancement in Microsphere Preparation Using Natural Polymers and Recent Patents
Recent Patents on Drug Delivery & Formulation